Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following drugs is known to have low first pass metabolism?

Theophylline. ***Theophylline*** - **Theophylline** exhibits **low first-pass metabolism**, meaning a significant portion of the orally administered drug reaches systemic circulation unchanged. - This characteristic contributes to its relatively **high bioavailability** when given orally. *Lidocaine* - **Lidocaine** undergoes extensive **first-pass metabolism** in the liver, leading to very low oral bioavailability. - Due to this, it is typically administered **parenterally** (e.g., intravenously or topically) to achieve therapeutic concentrations. *Propranolol* - **Propranolol** is known for its significant **first-pass metabolism**, which results in a much lower bioavailability after oral administration compared to intravenous. - This extensive metabolism necessitates higher oral doses to achieve the same therapeutic effect as parenteral administration. *Morphine* - **Morphine** also undergoes substantial **first-pass metabolism** in the liver, where it is primarily glucuronidated. - This leads to a lower oral bioavailability compared to other routes of administration and contributes to a higher oral dose requirement.

Q: Which route of administration undergoes the maximum first pass metabolism?

Oral. ***Oral*** - Drugs administered orally are absorbed from the **gastrointestinal tract** and transported via the **portal vein** directly to the liver, where they undergo significant **first-pass metabolism** before reaching systemic circulation. - This hepatic metabolism can drastically reduce the **bioavailability** of the drug, requiring higher doses or alternative administration routes. *Intra-arterial* - This route delivers drugs directly into an **artery** supplying a target tissue or organ, largely bypassing systemic circulation and initial hepatic metabolism. - It is used for localized effects, such as **chemotherapy** for specific tumors, minimizing systemic exposure. *Rectal* - While a portion of rectally administered drugs may bypass the portal circulation by entering the **inferior and middle rectal veins**, a significant amount can still be absorbed into the superior rectal vein, which drains into the portal system. - This means rectal administration offers only **partial avoidance** of first-pass metabolism, making it less complete than IV or intra-arterial routes for bypassing the liver altogether. *Intravenous* - Drugs administered intravenously are delivered directly into the **systemic circulation**, completely bypassing the gastrointestinal tract and the liver's first-pass metabolism. - This route ensures **100% bioavailability** and rapid onset of action, as the drug immediately reaches its target.

Q: Which of the following factors influences the duration of action of a drug?

All of the options. ***All of the options*** - **Clearance** and **rate of elimination** are the primary determinants of how long a drug stays in the body at therapeutic levels, thus directly influencing its duration of action. - **Bioavailability** affects the intensity and onset but can influence the perceived duration if subtherapeutic concentrations are achieved. - The interplay of these pharmacokinetic parameters ultimately determines the drug's therapeutic window and frequency of dosing. *Clearance* - **Clearance** is the rate at which the active drug is removed from the body, primarily by the kidneys and liver. - A higher clearance generally leads to a shorter elimination half-life and a **shorter duration of action**, as the drug is removed more quickly from the systemic circulation. *Rate of elimination* - The **rate of elimination** directly dictates how quickly the concentration of a drug in the body decreases over time. - A faster elimination rate (shorter half-life) means the drug's effects will wear off sooner, resulting in a **shorter duration of action**. - This is quantified by the elimination rate constant (Kel) and half-life (t½). *Bioavailability* - **Bioavailability** refers to the fraction of an administered dose of unchanged drug that reaches the systemic circulation. - While bioavailability primarily affects the **peak concentration (Cmax)** and **intensity** of drug effect, it can indirectly influence duration. - If bioavailability is very low, therapeutic concentrations may not be sustained long enough, effectively shortening the **clinically relevant duration of action**. - However, two drugs with identical elimination rates but different bioavailabilities will have the same elimination half-life and similar duration at therapeutic doses.

Q: When two different chemicals act on two different receptors and their responses are opposite to each other on the same cell, this phenomenon is called?

Physiological antagonism. ***Physiological antagonism*** - This occurs when two drugs act on **different receptors** to produce **opposite physiological effects** within the same system or cell, effectively canceling each other out [1]. - A classic example is the opposing actions of **histamine** (causing bronchoconstriction) and **adrenaline** (causing bronchodilation) on the bronchi [1]. *Chemical antagonism* - This involves a direct **chemical interaction** between two drugs that results in the **inactivation of one or both** of them. - An example is the binding of **chelating agents** to heavy metals, forming an inert complex. *Reversible antagonism* - This describes antagonism where the antagonist binds to the receptor and can be **displaced by a higher concentration of the agonist**. - It does not specifically describe antagonists acting on different receptors or producing opposing physiological effects. *Competitive antagonism* - This occurs when an antagonist directly **competes with an agonist for the same binding site** on a receptor [1]. - The antagonist, while not producing a response itself, prevents the agonist from binding and activating the receptor.

Q: Which of the following act through G protein coupled receptors?

Ach Muscarinic receptors. ***Ach Muscarinic receptors*** - All five **muscarinic acetylcholine receptors (M1-M5)** are **G protein-coupled receptors (GPCRs)** that mediate the parasympathetic nervous system's effects. - Activation of these receptors leads to downstream signaling through various G proteins, influencing cellular functions like heart rate and smooth muscle contraction. *Insulin receptors* - Insulin receptors are **receptor tyrosine kinases (RTKs)**, not GPCRs. - Upon insulin binding, they undergo autophosphorylation and activate intracellular signaling cascades involving **IRS proteins**, leading to glucose uptake. *Ach Nicotinic receptors* - Nicotinic acetylcholine receptors are **ligand-gated ion channels**, not GPCRs. - They open an ion pore in response to acetylcholine binding, allowing ions like sodium to flow through, resulting in rapid depolarization. *GABA-A receptors* - GABA-A receptors are also **ligand-gated ion channels**, specifically anion channels that are permeable to chloride ions. - When GABA binds, they open, allowing chloride influx, which typically hyperpolarizes the neuron and inhibits neural activity.

Q: Which drug has the highest plasma protein binding?

Warfarin. ***Warfarin*** - **Warfarin** exhibits very **high plasma protein binding**, typically greater than 99%, primarily to albumin. - This high binding capacity means that only a small fraction of the drug is free and pharmacologically active. - Due to high protein binding, warfarin is susceptible to drug interactions when displaced from albumin. *Verapamil* - **Verapamil** has a relatively high plasma protein binding, around 90%, but it is not as high as warfarin. - Its binding is predominantly to **albumin** and alpha-1-acid glycoprotein. *Aspirin* - **Aspirin** (acetylsalicylic acid) has moderate plasma protein binding, usually between 50-90%, depending on the dosage. - It binds to **albumin** and can displace other protein-bound drugs. *GTN* - **Glyceryl trinitrate (GTN)** has moderate plasma protein binding, approximately 60%. - Its rapid onset and short duration of action are primarily due to its extensive first-pass metabolism and quick redistribution, rather than protein binding characteristics.

Q: What is the effect of adding epinephrine to lignocaine (a local anesthetic)?

Decreases absorption of local anesthetic. ***Decreases absorption of local anesthetic*** - Epinephrine causes **vasoconstriction** at the site of injection, which reduces the rate at which the local anesthetic is absorbed into the systemic circulation. - This slower absorption leads to a **higher concentration of the anesthetic** at the nerve fibers, prolonging its effect and reducing systemic toxicity. - This is the primary mechanism by which epinephrine enhances local anesthetic efficacy. *Increases distribution of local anesthetic* - The primary effect of epinephrine is to **localize the anesthetic** by reducing its systemic distribution. - This localization is achieved through **vasoconstriction**, which keeps the drug at the desired site rather than allowing it to distribute widely. *Decreases duration of local anesthetic* - By slowing absorption, epinephrine effectively **increases the duration of action** of the local anesthetic. - The anesthetic remains at the site of action for a longer period, providing **extended pain relief**. *Increases metabolism of local anesthetic* - Epinephrine does not directly affect the **metabolic rate** of local anesthetics. - The primary mechanism of metabolism for amides like lignocaine is in the **liver** by cytochrome P450 enzymes.

Q: Which of the following is not a phase I reaction?

Conjugation. ***Conjugation*** - **Conjugation** reactions are characteristic of **phase II metabolism**, where a polar molecule is added to the drug to increase its water solubility and facilitate excretion. - This process is distinct from phase I reactions which primarily involve exposure of functional groups. *Oxidation* - **Oxidation** is a primary **phase I metabolic reaction**, often mediated by cytochrome P450 enzymes. - It introduces or exposes a polar functional group on the drug molecule. *Reduction* - **Reduction** is another key **phase I metabolic reaction**, which involves the gain of electrons by a drug molecule. - This reaction can alter the drug's activity or prepare it for further metabolism. *Hydrolysis* - **Hydrolysis** is a **phase I metabolic reaction** that involves the cleavage of a chemical bond by water. - This process typically breaks down esters and amides, exposing functional groups.

Q: Which of the following best demonstrates the variability in drug responsiveness among individuals?

Quantal Dose Response Curve. ***Quantal Dose Response Curve*** - A **quantal dose-response curve** plots the percentage of individuals exhibiting a discrete, all-or-none effect against the log dose of a drug. - This curve directly illustrates the **variability in drug responsiveness** within a population by showing the range of doses required to produce a specific effect in different individuals. *Efficacy* - **Efficacy** refers to the maximum effect a drug can produce, regardless of the dose. - While efficacy is an important pharmacological parameter, it describes the drug's overall therapeutic potential, not the **individual variability** in response. *Potency* - **Potency** is a measure of the amount of drug needed to produce an effect of given intensity. - It relates to the absolute dose required for a particular effect but does not directly demonstrate the **inter-individual differences** in biological response. *Graded Dose Response Curve* - A **graded dose-response curve** depicts the relationship between the dose of a drug and the **magnitude of the effect** in a **single biological unit** (e.g., an individual, a tissue, or a cell). - This curve reflects the relationship between drug concentration and effect intensity, but not the **variability in response among different individuals** in a population.

Q: Which of the following drugs should be given in a sustained-release oral dosage form?

An antihypertensive with a plasma half-life of 3 hours. *An anti-arrhythmic drug with a plasma half life of 10 seconds used for acute treatment of PSVT* - An extremely short **half-life** (10 seconds) indicates a drug suitable for **rapid-onset, acute interventions**, where the effect is needed immediately and for a very brief duration, making sustained release impractical. - Drugs like **adenosine**, used for acute PSVT, are given intravenously as a rapid bolus due to their ultra-short half-life, not in an oral sustained-release form. *Anti inflammatory drugs with the plasma half life of 24 hours* - A long **half-life** (24 hours) typically means the drug can be administered **once daily** to maintain therapeutic concentrations, rendering a sustained-release formulation unnecessary. - Such drugs already provide **prolonged action** and do not benefit significantly from further extension of release. *Hypnotic drugs with a plasma half life of 2 hours* - While a 2-hour half-life for a hypnotic might suggest potential for sustained release to prolong sleep, the goal of hypnotics is often a **rapid onset and relatively short duration** to avoid hangover effects. - Sustained release might cause **daytime sedation** and interfere with normal wakefulness, which is generally undesirable for this class of drugs. ***An antihypertensive with a plasma half-life of 3 hours*** - A short **half-life** (e.g., 3 hours) often necessitates frequent dosing to maintain therapeutic levels, making a **sustained-release formulation desirable** for patient compliance and consistent drug exposure. - Sustained-release dosage forms are particularly useful for drugs requiring **long-term, stable plasma concentrations**, such as antihypertensives, to manage chronic conditions effectively.

Question 1

Which of the following drugs is known to have low first pass metabolism?

Accepted Answer

Theophylline

Answer

Lidocaine

Answer

Propranolol

Answer

Morphine

Question 2

Which route of administration undergoes the maximum first pass metabolism?

Accepted Answer

Oral

Answer

Intra-arterial

Answer

Rectal

Answer

Intravenous

Question 3

Which of the following factors influences the duration of action of a drug?

Accepted Answer

All of the options

Answer

Bioavailability

Answer

Clearance

Answer

Rate of elimination

Question 4

When two different chemicals act on two different receptors and their responses are opposite to each other on the same cell, this phenomenon is called?

Accepted Answer

Physiological antagonism

Answer

Chemical antagonism

Answer

Reversible antagonism

Answer

Competitive antagonism

Question 5

Which of the following act through G protein coupled receptors?

Accepted Answer

Ach Muscarinic receptors

Answer

Insulin receptors

Answer

Ach Nicotinic receptors

Answer

GABA-A receptors

Question 6

Which drug has the highest plasma protein binding?

Accepted Answer

Warfarin

Answer

Verapamil

Answer

Aspirin

Answer

GTN

Question 7

What is the effect of adding epinephrine to lignocaine (a local anesthetic)?

Accepted Answer

Decreases absorption of local anesthetic

Answer

Increases distribution of local anesthetic

Answer

Decreases duration of local anesthetic

Answer

Increases metabolism of local anesthetic

Question 8

Which of the following is not a phase I reaction?

Accepted Answer

Conjugation

Answer

Oxidation

Answer

Reduction

Answer

Hydrolysis

Question 9

Which of the following best demonstrates the variability in drug responsiveness among individuals?

Accepted Answer

Quantal Dose Response Curve

Answer

Potency

Answer

Efficacy

Answer

Graded Dose Response Curve

Question 10

Which of the following drugs should be given in a sustained-release oral dosage form?

Accepted Answer

An antihypertensive with a plasma half-life of 3 hours

Answer

An anti-arrhythmic drug with a plasma half life of 10 seconds used for acute treatment of PSVT

Answer

Anti inflammatory drugs with the plasma half life of 24 hours

Answer

Hypnotic drugs with a plasma half life of 2 hours

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?